Knowhow offering
|
| Title | Adalimumab Biosimilar |
| Knowhow is available for | Stable mAb production through 40 generations |
| Summary | Current Status of Technology:
Stage of Development
mAb production at shake flask level (unfed culture)
Clone and construct developed inhouse (unencumbered)
Vector and cell lines in-licensed from invitrogen
Key process parameters —
IMT_C11 clone 100% purity
Yield: ~170-200 mg/L (100 ml culture vol. in 500 ml shake flask; unfed culture; repeated 3 times)
|
| Advantages | 1. Inhouse developed, stable, unencumbered CHO cell clone (IMT_C11) (mycoplasma free and functional)
2. Produces : Adalimumab ~170-200 mg/L (100 ml culture vol. in 500 ml shake flask; unfed culture; repeated 3 times)
3. Shows stable mAb production through 40 generations
|
|
Knowhow is listed under following categories
|
Knowhow from
| |
| Scientific/ engineering subject areas |
Life sciences/ biosciences & engineering |
| Investor interest categories |
Biotechnology/ Biomedical/ Health Technologies |
| Industries |
Pharmaceuticals, Bulk Drugs, Formulations |
| Customer categories and nature of business |
Businesses and other industries (B2B) |
| Technology readiness levels
|
|
|
Related documents:
|
|
(Local uploaded copy)
|
|
Database reference
|
| Database record number |
20220309070030 |
| Date of upload |
10 / Mar / 2022 |
| Date of update |
|
| URL to site when communicating about this knowhow |
http://techex.in/khdb/viewrecord.php?recordno=20220309070030 |
| Request for this technology |
Click here for Request Form |
